Neospora caninum p38 antibody and antigen (recombinant protein)
Diagnostic anti-Neospora caninum p38 antibodies pairs and antigen for animal health (animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease Neosporosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Multiple species disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-VT-P250-Tg001-Ag01 | Recombinant Neospora caninum p38 protein | $3090.00 |
GMP-VT-P250-Tg001-Ab01 | Anti-Neospora caninum p38 mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P250-Tg001-Ab02 | Anti-Neospora caninum p38 mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P250-Tg001-Ab03 | Anti-Neospora caninum p38 human monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P250-Tg001-Ab04 | Anti-Neospora caninum p38 human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-VT-P250-Tg001-Ag01 |
Product Name | Recombinant Neospora caninum p38 protein |
Pathogen | Neospora caninum |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Neospora caninum p38 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Neospora caninum level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease with Neosporosis. |
Tag | His | Product description | Recombinant Neospora caninum p38 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P250-Tg001-Ab01,GMP-VT-P250-Tg001-Ab02 |
Pathogen | Neospora caninum |
Product Name | Anti-Neospora caninum p38 mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Neospora caninum p38 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Neospora caninum antibodies in Neospora caninum level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease with Neosporosis. |
Product description | Anti-Neospora caninum p38 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Neospora caninum antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P250-Tg001-Ab03,GMP-VT-P250-Tg001-Ab04 |
Pathogen | Neospora caninum |
Product Name | Anti-Neospora caninum p38 human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Neospora caninum p38 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Neospora caninum antibodies in Neospora caninum level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease with Neosporosis. |
Product description | Anti-Neospora caninum p38 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Pathogen Information
Neospora caninum: Understanding a Protozoan Parasite
Neospora caninum, often referred to simply as Neospora, is a protozoan parasite of significant veterinary importance. In this comprehensive overview, we delve into the pathogen's taxonomy, structure, hosts, associated diseases, and diagnostic methods, shedding light on its complex biology and the critical need for management strategies.
Taxonomy and Classification:
Neospora caninum belongs to the kingdom Protista within the phylum Apicomplexa. This classification places it in the company of well-known parasitic organisms such as Toxoplasma gondii and Plasmodium spp., which cause diseases like toxoplasmosis and malaria, respectively. As a protozoan, Neospora caninum is eukaryotic, characterized by its single-celled structure and intracellular lifestyle.
Pathogen Structure and Key Molecules:
At the heart of Neospora caninum's infectious capabilities are its genes and proteins. The pathogen employs a range of molecular tools for host cell invasion and survival. Notable components include:
Surface Antigens: These genes and proteins are pivotal in recognizing and adhering to host cells, facilitating the initial stages of infection.
Rhoptry Proteins: Critical for the formation of the parasitophorous vacuole, a protective compartment within the host cell where the parasite resides.
Dense Granule Proteins: These molecules modulate host cell processes to create a suitable environment for Neospora's survival.
SAG1 (Surface Antigen 1): SAG1 is a well-studied protein used not only in diagnostic assays but also holds potential in the development of vaccines and targeted interventions.
Hosts and Associated Diseases:
Neospora caninum's life cycle involves two primary host categories - the definitive host (canids) and intermediate hosts (cattle and other livestock). In cattle, Neospora caninum infections can result in a condition known as neosporosis. This infectious disease is marked by adverse outcomes, including abortion, stillbirths, and neurological disorders in affected bovine neonates. The impact on the livestock industry can be economically significant due to reduced productivity and reproductive losses.
In the definitive host, typically dogs, Neospora caninum infections are often asymptomatic or exhibit mild clinical symptoms. However, these animals play a crucial role in the lifecycle of the parasite, shedding oocysts into the environment, which can infect intermediate hosts.
Diagnostic Methods:
Accurate diagnosis is paramount for the effective management of Neospora caninum infections. Several diagnostic methods are available:
Serological Tests: Enzyme-linked immunosorbent assays (ELISA) targeting specific Neospora antigens, such as SAG1, are used to detect antibodies in the blood or serum, indicating exposure or active infection.
Polymerase Chain Reaction (PCR): Nucleic acid-based assays, often targeting genes like Nc5 or ITS1, enable the detection of Neospora DNA in biological samples.
Immunohistochemistry: This technique helps identify the presence of Neospora antigens in tissue samples, aiding in the diagnosis of infections in affected animals.
Histopathology: Examination of tissue samples for characteristic Neospora-induced lesions, an important method, particularly in post-mortem examinations.
In conclusion, Neospora caninum, as a member of the Apicomplexa phylum, stands as a parasitic threat to livestock, with cattle being the primary intermediate host. The parasite's complex molecular structure and the availability of diagnostic methods targeting genes and proteins like SAG1 underline the need for research and biopharmaceutical developments to mitigate its impact on the agriculture industry and animal health. Further understanding of Neospora's biology opens the door to the potential development of effective management strategies and vaccines to reduce the economic losses associated with neosporosis.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.